Table Graph
   

chloroquine and derivatives - versus standard of care - for COVID 19 hospitalized pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 1.10 [0.98, 1.22]< 10%3 studies (3/-)5.0 %some concernnot evaluable moderatecrucial-
deaths 1.10 [0.99, 1.22]< 10%20 studies (20/-)3.9 %some concernlow moderatecrucial-
deaths (time to event analysis only) 1.10 [0.99, 1.23]< 10%2 studies (2/-)3.9 %some concernnot evaluable moderatecrucial-
clinical deterioration 1.02 [0.54, 1.93]< 118%3 studies (3/-)48.0 %some concernnot evaluable moderateimportant-
clinical improvement 1.01 [0.59, 1.74]> 10%1 study (1/-)51.7 %NAnot evaluable important-
clinical improvement (14-day) 0.79 [0.47, 1.33]> 10%2 studies (2/-)18.5 %some concernnot evaluable moderateimportant-
clinical improvement (time to event analysis only) 0.88 [0.67, 1.16]> 10%2 studies (2/-)18.7 %some concernnot evaluable moderateimportant-
death or ventilation 1.14 [1.03, 1.25]< 10%2 studies (2/-)0.5 %some concernnot evaluable moderateimportant-
hospital discharge 0.88 [0.64, 1.21]> 10%1 study (1/-)21.0 %NAnot evaluable important-
radiologic improvement (7-day) 3.43 [1.10, 10.70]> 10%1 study (1/-)98.3 %NAnot evaluable important-
viral clearance 0.83 [0.57, 1.21]> 10%2 studies (2/-)17.2 %highnot evaluable lowimportant-
viral clearance (time to event analysis only) 0.85 [0.58, 1.23]> 10%1 study (1/-)19.3 %NAnot evaluable important-
viral clearance by day 14 1.42 [0.26, 7.76]> 10%1 study (1/-)65.5 %NAnot evaluable important-
ICU admission 1.19 [0.72, 1.96]< 14%2 studies (2/-)24.6 %some concernnot evaluable moderatenon important-

safety endpoints 00

cardiac arrest 1.92 [0.35, 10.49]< 10%1 study (1/-)22.7 %NAnot evaluable important-
adverse events 1.99 [1.10, 3.61]< 146%6 studies (6/-)1.1 %some concernnot evaluable moderatenon important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.



 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons